Gene · 2071
Papers2,382
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 2,382
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Enhanced frequency of transcription pre-initiation complexes assembly after exposure to UV irradiation results in increased repair activity and reduced probabilities for mutagenesis. | Nucleic Acids Res | 2023 | 37470822 | PubTator, text mining | PubMed |
| Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel. | J Med Genet | 2023 | 37451831 | PubTator, text mining | PubMed |
| Cisplatin in Liver Cancer Therapy. | Int J Mol Sci | 2023 | 37446035 | PubTator, text mining | PubMed |
| G-quadruplex DNA contributes to RNA polymerase II-mediated 3D chromatin architecture. | Nucleic Acids Res | 2023 | 37427784 | PubTator, text mining | PubMed |
| ASH1L-MRG15 methyltransferase deposits H3K4me3 and FACT for damage verification in nucleotide excision repair. | Nat Commun | 2023 | 37393406 | PubTator, text mining | PubMed |
| Comparing methods for drug-gene interaction prediction on the biomedical literature knowledge graph: performance versus explainability. | BMC Bioinformatics | 2023 | 37391722 | PubTator, text mining | PubMed |
| Repeatedly next-generation sequencing during treatment follow-up of patients with small cell lung cancer. | Medicine (Baltimore) | 2023 | 37390276 | PubTator, text mining | PubMed |
| STAT3-Mediated Promoter-Enhancer Interaction Up-Regulates Inhibitor of DNA Binding 1 (ID1) to Promote Colon Cancer Progression. | Int J Mol Sci | 2023 | 37373188 | PubTator, text mining | PubMed |
| Deep intronic founder mutations identified in the ERCC4/XPF gene are potential therapeutic targets for a high-frequency form of xeroderma pigmentosum. | Proc Natl Acad Sci U S A | 2023 | 37364129 | PubTator, text mining | PubMed |
| Exploring Prognostic Biomarkers of Acute Myeloid Leukemia to Determine Its Most Effective Drugs from the FDA-Approved List through Molecular Docking and Dynamic Simulation. | Biomed Res Int | 2023 | 37359050 | PubTator, text mining | PubMed |
| Quantitative profiling of genes associated with cancer pathways in brain tumors. | Klin Onkol | 2023 | 37353350 | PubTator, text mining | PubMed |
| The French Cohort of DNA Repair-Deficient Xeroderma Pigmentosum Patients: Risk of Hematological Malignancies. | Cancers (Basel) | 2023 | 37345043 | PubTator, text mining | PubMed |
| Structural polymorphism of the PH domain in TFIIH. | Biosci Rep | 2023 | 37340985 | PubTator, text mining | PubMed |
| Promoter-proximal nucleosomes attenuate RNA polymerase II transcription through TFIID. | J Biol Chem | 2023 | 37330174 | PubTator, text mining | PubMed |
| Triptolide enhances carboplatin-induced apoptosis by inhibiting nucleotide excision repair (NER) activity in melanoma. | Front Pharmacol | 2023 | 37324464 | PubTator, text mining | PubMed |
| Dissection of DNA damage and repair pathways in live cells by femtosecond laser microirradiation and free-electron modeling. | Proc Natl Acad Sci U S A | 2023 | 37307476 | PubTator, text mining | PubMed |
| LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair. | Oncotarget | 2023 | 37306526 | PubTator, text mining | PubMed |
| A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21. | J Biol Chem | 2023 | 37301510 | PubTator, text mining | PubMed |
| The Epidermal Transcriptome Analysis of a Novel c.639_642dup LORICRIN Variant-Delineation of the Loricrin Keratoderma Pathology. | Int J Mol Sci | 2023 | 37298411 | PubTator, text mining | PubMed |
| Novel Association of Trichothiodystrophy with Autoimmune Thyroiditis and Autoimmune Hemolytic Anemia: A Case Report. | Indian Dermatol Online J | 2023 | 37266075 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2071/papers?page=8